NCT06770452View on ClinicalTrials.gov

HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 25, 2025

Primary Completion Date

February 1, 2027

Study Completion Date

February 1, 2028

Conditions
Metastatic Pancreatic Carcinoma
Interventions
DRUG

HRS-4642

HRS-4642 is a KRAS G12D inhibitor

DRUG

Nimotuzumab

Nimotuzumab is a humanized IgG 1 monoclonal antibody targeting EGFR

DRUG

gemcitabine + nab-paclitaxel

Albumin paclitaxel 125mg/m2 intravenous infusion, gemcitabine 1000mg / m2, D1,8, a cycle every 3 weeks

Trial Locations (2)

310000

NOT_YET_RECRUITING

First Affiliated Hospital of Zhejiang University Schlool of Medicine, Hangzhou

RECRUITING

The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

Zhejiang University

OTHER